

Summary of Product Characteristics

1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Advantage 80 Spot-on solution for Cats

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:	Quantity:
Imidacloprid	80 mg/pipette (0.8 ml of a 10 % solution)

Excipient(s):
Butylhydroxytoluene (E 321) 0.8 mg/pipette

For full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Spot-on solution.
Clear yellow to slightly brownish solution.

4 CLINICAL PARTICULARS

4.1 Target Species

Cats.

4.2 Indications for use, specifying the target species

For the prevention and treatment of flea infestations on cats of 4 kg body weight and greater.
For cats of less than 4 kg body weight use Advantage 40 for Cats.
One treatment prevents further flea infestation for three to four weeks.
The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary surgeon.

4.3 Contraindications

Do not treat unweaned kittens of less than 8 weeks of age.
Do not use in animals that are known to be hypersensitive to the active substance or any of the excipients.

4.4 Special warnings for each target species

None.

4.5 Special precautions for use

Special precautions for use in animals:

This product is for topical use and should not be administered orally.
Care should be taken to avoid the contents of the pipette coming into contact with the eyes or mouth of the recipient animal.
Do not allow recently treated animals to groom each other.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands thoroughly after use.
Wash off any skin contamination with soap and water.
People with known skin sensitivity may be particularly sensitive to this product.

Avoid contact of the product with the eyes or mouth.

If the product gets into eyes accidentally, the eyes should be thoroughly flushed with water. If skin or eye irritation persists, or the product is accidentally swallowed, obtain medical attention.

Do not eat, drink or smoke during application.

4.6 Adverse reactions (frequency and seriousness)

The product is bitter tasting and salivation may occasionally occur if the cat licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment (see also section 4.9 *Amounts to be administered and administration route*).

In very rare occasions skin reactions such as hair loss, redness, itching and skin lesions may occur. Agitation has also been reported. Excessive salivation and nervous signs such as incoordination, tremors and depression have been reported exceptionally in cats.

4.7 Use during pregnancy, lactation or lay

No primary embryotoxic, teratogenic or reproductive toxic effects have been observed during the studies with imidacloprid on rats and rabbits. Studies on pregnant and lactating queens together with their offspring are limited. Evidence so far suggests that no adverse effects are to be expected in these animals.

4.8 Interaction with other medicinal products and other forms of interactions

No incompatibility has been observed between this product at twice the recommended dose and the following commonly used veterinary products: lufenuron, pyrantel and praziquantel. The compatibility of the product was also demonstrated with a wide range of routine treatments under field conditions including vaccination.

4.9 Amounts to be administered and administration route

Dosage and Treatment Schedule


Cat (kg bw)	Product	Number of Pipettes	Imidacloprid (mg/kg bw)
< 4 kg	Advantage 40 for Cats	1 x 0.4 ml	minimum of 10
≥ 4 kg	Advantage80 for Cats	1 x 0.8 ml	minimum of 10

Re-infestation from emergence of new fleas in the environment may continue to occur for six weeks or longer after treatment is initiated. More than one treatment may therefore be required, depending on the level of fleas in the environment. To aid in environmental challenge, the additional use of a suitable environmental treatment against adult fleas and their developing stages is recommended.

The product remains effective if the animal becomes wet, for example after exposure to heavy rain. However, re-treatment may become necessary, depending on the presence of fleas in the environment. In these cases do not re-treat more frequently than once weekly.

Method of Administration

Remove one pipette from the package. Hold pipette in an upright position, twist and pull off cap. Use reversed cap to twist and remove seal from pipette.



Part the hair on the cat's neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze firmly several times to empty the contents directly onto the skin.



The product is bitter tasting and salivation may occasionally occur if the cat licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Application at the base of the skull will minimize the opportunity for the cat to lick the product.

Apply only to undamaged skin. Do not allow recently treated animals to groom each other.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse clinical signs were produced using doses of five times the therapeutic level weekly for eight consecutive weeks. In rare cases of overdose or licking of treated fur, nervous system disorders (such as twitching, tremors, ataxia, mydriasis, miosis, lethargy) can occur.

Poisoning following inadvertent oral uptake in animals is unlikely. In this event, treatment should be symptomatic under veterinary medical attention. There is no known specific antidote but administration of activated charcoal may be beneficial.

4.11 Withdrawal period(s)

Not applicable.

5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: antiparasitic agent
ATC vet code: QP53AX17

5.1 Pharmacodynamic properties

Imidacloprid, 1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine * is an ectoparasiticide belonging to a group of chloronicotinyl compounds. Chemically, it is more accurately described as a chloronicotinyl nitroguanidine.

The substance has a high affinity for the nicotinic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS). The ensuing inhibition of cholinergic transmission in insects results in paralysis and death. Due to the weak nature of the interaction with mammalian nicotinic receptor sites and the postulated poor penetration through the blood/brain barrier in mammals, it has virtually no effect on the mammalian CNS. The minimal pharmacological activity in mammals is supported by safety studies involving systemic administration of sub-lethal doses to rabbits, mice and rats.

In further studies, in addition to the adulticide flea efficacy of imidacloprid, a larvicidal flea efficacy in the surroundings of the treated pet has been demonstrated. Larval stages in the pet's surroundings are killed following contact with a treated animal.

5.2 Pharmacokinetic particulars

The product is indicated for cutaneous administration. Following topical application in cats, the solution is quickly distributed over the animal. Acute dermal studies in the rat and target animal overdose and serum kinetic studies have established that

systemic absorption is very low, transient and not relevant for the clinical efficacy. This has been further demonstrated by a study in which fleas were not killed after having fed on previously treated animals once the animal's skin and fur had been cleaned of all active material.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Butylhydroxytoluene E321
Benzyl alcohol
Propylene carbonate

6.2 Major incompatibilities

None known.

6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale: 5 years

6.4 Special precautions for storage

No special storage conditions required.
Store away from food, drink and animal feeding stuffs.

6.5 Nature and composition of immediate packaging

Pack sizes 0.8 ml solution per pipette
Pack containing 1, 2, 3, 4, or 6 unit dose pipettes

Container White polypropylene pipettes with caps

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Any unused product or waste materials should be disposed of in accordance with national requirements.

7 MARKETING AUTHORISATION HOLDER

Elanco GmbH
Heinz-Lohmann-Strasse 4
27472 Cuxhaven
Germany

8 MARKETING AUTHORISATION NUMBER(S)

VPA22020/045/002

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 23 February 2001
Date of last renewal: 06 August 2007

10 DATE OF REVISION OF THE TEXT

October 2020

16 October 2020

CRN009PN1

Page 4 of 4